ABUS done at a facility with a low price means that the machine will not take as detailed images as a study done for a higher price.
The market leader for ABUS in North America is the GE Invenia. It has the largest install base in Canada, with most units in Alberta and only 3 (as of 2019) in Ontario. Only ONE model of this machine is available for sale. A study done on ANY GE Invenia ABUS has the SAME capability (because only one type of this machine is sold). The differences in quality will be determined by the personnel that operate the machine and the Radiologist that reports the study, as we have discussed in the other “Facts” in this section. ABUS, in an ideal world, should be available to all women older than 40 years with dense breasts. At the Toronto Centre for Medical Imaging (TCFMI), our motivation to purchase an ABUS unit was to make this study available to as many women with dense breasts as possible. As you are aware, ABUS will find small breast cancers that could be missed on mammography in women with dense breasts. These cancers found on ABUS are generally small and can be treated easily.
The price for this study at TCFMI is comparable to what is being charged by clinics in the US, where they have the most experience with ABUS. In order to be true to our purpose for making the test as widely available as possible, we have priced it lower than what you may have thought. This lower price also happens to be comparable to other services that our patients access annually or semi-annually, such as regular dental or eye check ups. And patients who get their ABUS at TCFMI have the added benefit of integrating the results of ABUS with traditional hand held ultrasound, mammography and biopsy, if necessary, all under one roof.